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ABSTRACT
PROX1 is a transcription factor with an essential role in embryonic development 
and determination of cell fate. In addition, PROX1 has been ascribed suppressive as 
well as oncogenic roles in several human cancers, including brain tumors. In this 
study we explored the correlation between PROX1 expression and patient survival in 
high-grade astrocytomas. For this purpose, we analyzed protein expression in tissue 
microarrays of tumor samples stratified by patient age and IDH mutation status. We 
initially screened 86 unselected high-grade astrocytomas, followed by 174 IDH1-
R132H1 immunonegative glioblastomas derived from patients aged 60 years and 
older enrolled in the Nordic phase III trial of elderly patients with newly diagnosed 
glioblastoma. Representing the younger population of glioblastomas, we studied 80 
IDH-wildtype glioblastomas from patients aged 18-60 years. There was no correlation 
between PROX1 protein and survival for patients with primary glioblastomas included 
in these cohorts. In contrast, high expression of PROX1 protein predicted shorter 
survival in the group of patients with IDH-mutant anaplastic astrocytomas and 
secondary glioblastomas. The prognostic impact of PROX1 in IDH-mutant 1p19q 
non-codeleted high-grade astrocytomas, as well as the negative findings in primary 
glioblastomas, was corroborated by gene expression data extracted from the Cancer 
Genome Atlas. We conclude that PROX1 is a new prognostic biomarker for 1p19q 
non-codeleted high-grade astrocytomas that have progressed from pre-existing low-
grade tumors and harbor IDH mutations.
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INTRODUCTION
Glioblastomas are the most common and lethal 
type of adult primary brain tumors [1,2]. Mean survival 
for patients with glioblastoma is around 15 months 
[3]. Traditionally, glioblastomas are separated into 
two major classes; primary glioblastomas that arise de 
novo in predominantly older patients and secondary 
glioblastomas in younger patients with a history of prior 
low-grade gliomas. Recent advances in cancer genomics 
have provided support for distinctive molecular correlates 
of these two clinical phenotypes. Primary glioblastomas 
are characterized by PTEN tumor suppressor mutations/
deletions, EGFR amplification and TERT promoter 
mutations, whereas secondary glioblastomas frequently 
have mutations/deletions of IDH1/2, TP53 and ATRX [4]. 
In the 2016 WHO classification of brain tumors, some of 
these key aberrations have been added to define new tumor 
entities based on histological and molecular features [5]. 
Importantly, the identification of distinctive molecular 
pathways has introduced new concepts for therapeutic 
management, based on the clinical diversity of these 
tumors. 
Cancer development is caused by defective 
regulation of cell growth, differentiation, death and/or 
survival. While cancer cells can inactivate elements of 
all these pathways, they never disable the entire signaling 
cascades [6]. One of the most fundamental traits of cancer 
cells involves their self-renewal capability and ability to 
sustain proliferation. Identifying aberrant expression of 
key regulatory proteins of these signaling pathways is an 
important step to unravel oncogenic mechanisms, guide 
therapeutic decisions and develop new biologically based 
therapies. 
PROX1 is a transcription factor with a widespread 
role in cell cycle control and progenitor cell differentiation 
that is critical for embryonic development [7]. During 
development of the CNS, PROX1 regulates progenitor 
cell differentiation and initiation of neurogenesis, 
where high levels lead to depletion of the progenitor 
cell pool. Expression of PROX1 in the developing and 
adult mammalian brain corresponds to areas known to 
harbor neural progenitor and neural stem cells, i.e. the 
subventricular zone of the lateral ventricle wall and the 
subgranular zone in the dentate gyrus [8-10]. In addition 
to its role in physiological development, PROX1 has been 
ascribed tumor suppressive as well as oncogenic effects in 
human cancers [7]. 
We have previously shown that the proportion 
of PROX1 expressing tumor cells correlates with the 
malignancy grade of gliomas [11], and that increased 
PROX1 protein expression predicts shorter survival for 
patients with diffuse low-grade gliomas [12]. The aim 
of the present study was to determine the prognostic 
impact of PROX1 in high-grade astrocytomas. We 
hypothesized that PROX1 is a prognostic factor for 
patients with primary glioblastomas, the most common 
type of glioblastoma that arises in older patients and 
lacks IDH1/2 mutations. Alternatively, and based on our 
previous findings in diffuse low-grade gliomas, PROX1 
may be a prognostic marker for IDH-mutant astrocytomas 
that have progressed from pre-existing low-grade tumors 
[12]. For this purpose, we used tissue microarrays (TMAs) 
of high-grade astrocytomas representing the different 
pathways based on IDH mutation status. Since age is 
one of the strongest predictors of survival for patients 
with glioblastomas, separate analyses were performed for 
younger and older patients [13]. 
Figure 1 illustrates the study design. For screening, 
we used an unselected cohort of 86 adult patients with 
high-grade astrocytomas receiving radiotherapy (RT) 
at our hospital. Representing the older population of 
primary glioblastoma, we selected 174 IDH1-R132H1 
immunonegative tumors from patients aged ≥ 60 years 
enrolled in the Nordic phase III trial in elderly patients 
with newly diagnosed glioblastomas, comparing standard 
RT, hypofractionated RT and temozolomide (TMZ) 
[14]. The first results of this TMA are presented here. 
Representing the younger population, 80 IDH-wildtype 
glioblastomas were derived from a treatment cohort 
with patients aged < 60 years receiving RT and different 
treatment schedules of TMZ. We found that PROX1 
protein levels did not predict survival in these cohorts. 
In contrast, PROX1 protein expression correlated with 
survival in 34 IDH-mutant high-grade astrocytomas. In 
a final step, these findings were corroborated in IDH-
wildtype glioblastomas and in IDH-mutant 1p19q non-
codeleted high-grade astrocytomas extracted from The 
Cancer Genome Atlas (TCGA). The potential role of 
PROX1 as a pathway-specific biomarker for astrocytomas 
is discussed.
RESULTS
UNSELECTED COHORT OF HIGH-GRADE 
ASTROCYTOMAS (Table 1)
Screening cohort of high-grade astrocytomas 
(n = 86)
A TMA was constructed from a retrospective cohort 
of adult patients with high-grade gliomas receiving RT 
at our hospital, as previously described [15]. Tumors 
diagnosed as astrocytomas WHO grade III and IV, based 
on histological classification were collected for the 
present study. Fifteen of the 86 tumor samples showed 
immunoreactivity for mutant R132H IDH1 protein 
(mIDH1R132) [16]. The clinical characteristics of the 
patients included in the screening cohort are shown in 
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Table 1. Mean age was 57 years, mean survival 12.7 
months. All patients had died at the end of the study. 
The parameter age, entered as continuous variable in 
the multivariate Cox regression model, correlated with 
survival, whereas gender, Karnofsky performance status 
(KPS ≥ 80 versus KPS < 80), surgery (resection versus 
biopsy), WHO malignancy grade (grade III versus IV) and 
IDH1 mutated protein (mutated versus non-mutated) did 
not affect survival (Table 1). 
Immunostaining of PROX1
PROX1 protein was localized in the nucleus of the 
tumor cells. Immunopositive tumor cells for the anti-
PROX1 antibody were detected in all samples. Protein 
expression was scored as 1+ (< 50% positive tumor cells), 
2+ (50-90% positive tumor cells) or 3+ (≥ 90% positive 
tumor cells), as illustrated in Figure 2. Table 1 shows 
the distribution of PROX1 protein in the different tumor 
samples included in the TMA. In general, PROX1 was 
widely expressed in the majority of tumors. Eight samples 
were scored with less than 50% positive cells, 41 samples 
were scored with 50-90% positive cells, and 37 samples 
had more than 90% positive cells (Table 1). 
Screening cohort: survival by PROX1 protein 
expression
As shown in Table 1, age was a statistically 
significant prognostic factor whereas PROX1 was not 
identified as a predictor for survival in the Cox regression 
model (p = 0.56). These findings in the screening cohort 
prompted us to explore the correlation between PROX1 
protein expression and survival in two age-specific cohorts 
of glioblastoma, the results of which are presented in 
detail below. 
SELECTED COHORTS OF PRIMARY 
GLIOBLASTOMAS (Table 2)
Elderly patients with newly diagnosed 
glioblastomas (n = 174) 
A TMA was generated from patients aged 60 years 
or older with glioblastoma enrolled in the Nordic trial 
of elderly patients with newly diagnosed glioblastomas 
Table 1: Cox multivariate regression in high-grade astrocytomas for patients included 
in the screening cohort (n = 86) 
Variables n HR (95% CI) p-value
Gender (female vs male) 48/38 1.07 (0.68-1.69) 0.76
Age 86 1.03 (1.01-1.05 0.0038*
Performance status (KPS ≥80 vs <80) 71/15 0.94 (0.52-1.68) 0.83
Surgery (resection vs biopsy) 81/5 1.20 (0.43-3.37) 0.72
Malignancy grade (WHO III vs IV) 19/67 0.66 (0.35-1.23) 0.19
IDH1 (mutation vs no mutation) 15/71 0.76 (0.38-1.52) 0.44
PROX1 protein (<50%; 50-90%; >90%) 8/41/37 1.12 (0.76-1.67) 0.56
HR= hazard ratio; CI = confidence interval; *p ≤ 0.05
Figure 1: Illustration of the study design. We used tissue microarrays (TMAs) to explore PROX1 protein signatures in an unselected 
screening cohort of astrocytomas grade III and IV, in cohorts of primary glioblastomas stratified by age and in IDH-mutant astrocytomas 
grade III and IV. In the final step, gene expression data extracted from The Cancer Genome Atlas (TCGA) in 1p19q non-codeleted 
astrocytomas grade III and IV that were stratified by IDH mutation status were used to corroborate the findings. 
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[14]. This TMA consisted of 175 surgical samples from 
the original 342 randomized patients, selected based on 
the availability of tumor tissues and on informed consent 
to use samples for translational studies at the local 
centers. For the present study, we excluded one tumor 
with immunoreactivity for the mutated IDH1 protein 
(mIDH1R132), leaving a total number of 174 tumors 
[16]. DNA sequencing of IDH1/2 mutations was not 
performed. The clinical and molecular characteristics 
of the 174 elderly patients with IDH1-immunonegative 
glioblastomas are shown in Table 2a. Mean age was 
69.3 years, mean survival was 10.4 months (range 0.4-
126 months). At the time of last follow-up (1st January 
2011), 169 patients had died, 3 were alive, and 2 were 
lost to follow-up. Multivariate survival analysis by Cox 
regression identified WHO Performance Scale (0-1 versus 
2-3), MGMT promoter methylation status (methylated 
versus unmethylated) and steroids at baseline (yes versus 
no) as independent prognostic factors, while surgery 
(resection versus biopsy), age (continuous) and treatment 
arm (standard / hypofractionated RT versus TMZ) did not 
reach significance (Table 2a).
Survival by PROX1 in elderly patients with newly 
diagnosed glioblastomas
The distribution of PROX1 protein expressing cells 
in the tumors is shown in Table 2a. As for the screening 
cohort, PROX1 protein levels were generally high. There 
was no correlation between PROX1 protein expression 
and survival in the multivariate Cox regression model (p 
= 0.28) (Table 2a). Similar negative results were found 
for the three treatment arms separately (data not shown). 
There were no statistically significant pairwise interactions 
between PROX1 and the other variables in the model.
Younger patients with IDH-wildtype glioblastomas 
(n = 80)
Representing the younger population of primary 
glioblastomas, we used a TMA constructed from patients 
with high-grade gliomas aged 18-60 years. Patients were 
enrolled in a treatment cohort with RT or RT plus TMZ in 
various combinations, and 82 IDH-wildtype glioblastomas 
were selected from this TMA. Two samples with 
combined losses of 1p and 19q (1p19q codeletion) were 
excluded, leaving a total number of 80 tumors. Twelve 
patients received RT only as primary treatment, 68 patients 
received RT with TMZ. Table 2b shows the clinical and 
molecular characteristics of these 80 patients younger than 
60 years with IDH-wildtype glioblastomas. Mean age was 
51.4 years (range 24-60), mean survival was 26.5 months 
(range 0.5-129 months). At the time of last follow-up, 75 
patients had died and 5 patients were alive. Multivariate 
analysis by Cox regression identified methylated MGMT 
promoter (p = 0.0326) and no steroids at baseline (p = 
0.0070) as statistically significant favorable prognostic 
factors, while age (< 50 versus ≥ 50-60 years), gender and 
treatment (RT versus RT with TMZ) did not affect survival 
(Table 2b). WHO performance status (WHO 0-1, n = 73 
versus 2, n = 7) and surgery (resection, n = 77 versus 
biopsy, n = 3) were not included in the model due to the 
uneven distribution of these parameters.
Survival by PROX1 in younger patients with 
IDH-wildtype glioblastomas
The distribution of PROX1 protein in the 80 IDH-
wildtype glioblastomas from patients aged 18-60 years is 
shown in Table 2b. There was no statistically significant 
correlation between PROX1 expression and survival in the 
Table 2a: Multivariate Cox regression in primary glioblastomas for patients 60 years and older (n = 174)
First line Treatment
Variables
Standard RT 
(n =  49)
Hypo RT
(n = 58)
TMZ
(n = 67)
HR#
(95% CI) p-value
Gender (female vs male) 14/35 32/26 25/42 0.79 (0.54-1.15) 0.22
Age (60-70 vs > 70) 34/15 34/24 36/31 1.08 (0.75-1.55) 0.68
WHO Performance Status  (0-1 vs 2-3) 36/13 48/10 51/16 0.52 (0.33-0.81) 0.004*
Surgery type (resection vs biopsy) 44/5 54/4 60/7 0.57 (0.30-1.08) 0.08
Taking steroids at baseline (no vs yes) 23/25(1 m) 31/27
35/31
(1 m) 0.51 (0.35-0.74) 0.0004*
Radiotherapy (standard + hypo vs TMZ) 107 67 0.92 (0.64-1.32) 0.65
MGMT status (methyl vs unmethyl) 15/29(5 m)
25/25
(8 m)
22/36
(9 m) 0.69 (0.48-0.99) 0.047*
PROX1 protein
(<50%; 50-90%; >90%)
15/12/20 
(2 m)
10/11/33 
(4 m)
16/22/25 
(4 m) 0.89 (0.71-1.10) 0.28
HR= hazard ratio; CI = confidence interval; m = missing data
#n = 141 patients in the multivariate analysis; *p ≤ 0.05
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Cox regression model (p = 0.54) (Table 2b). There were 
no pairwise interactions between PROX1 and the other 
variables in the model.
SELECTION OF IDH-MUTANT 
ASTROCYTOMAS GRADE III-IV (Table 3)
IDH-mutant anaplastic astrocytomas and 
glioblastomas (n = 34)
We then focused on the population of IDH-mutant 
anaplastic astrocytomas and glioblastomas. The TMA 
from patients aged 18-60 years comprised 19 IDH-mutant 
1p19q non-codeleted high-grade astrocytomas, while the 
screening cohort comprised 15 high-grade astrocytomas 
that were immunopositive for mIDH1R132. The clinical 
characteristics of these 34 patients (20 IDH-mutant 
astrocytomas grade III, 14 IDH-mutant glioblastomas) 
are shown in Table 3. Mean age was 44.5 years (range 
23-77), mean survival was 49.8 months (range 4.0-
103.4). Because of the small sample size we used 50% 
as cut off value for PROX protein expression (instead of 
the 3-grading scale) in the statistical model. Univariate 
Kaplan-Meier model showed a statistically significant 
shorter survival for patients with tumors expressing high 
PROX1 protein (≥ 50% immunopositive tumor cells) (p 
= 0.009, Log-rank test) (Figure 3). The impact of PROX1 
together with age and malignancy grade (WHO grade III 
versus IV) was analyzed by multivariate Cox regression 
(Table 3). Low PROX1 protein and younger age were 
associated with statistically significant longer survival. 
MGMT promoter methylation status was available for only 
19/34 tumors and was not used in the model.
VALIDATION BY TCGA (Table 4)
IDH-wildtype glioblastomas (n = 103)
To validate the findings for PROX1 in high-grade 
astrocytomas we used the Cancer Genome Atlas (TCGA) 
Table 2b: Multivariate Cox regression in primary glioblastomas for patients younger than 60 years (n =80)
Variables n HR#(95% CI) p-value
Gender (female vs male) 32/48 0.98 (0.60-1.61) 0.94
Age (<50 vs 50-60) 23/57 0.99 (0.55-1.76) 0.96
Taking steroids at baseline (no vs yes) 56/24 0.48(0.29-0.82) 0.007*
MGMT status
(methyl vs unmethyl)
39/38
(3 m) 0.58 (0.35-0.96) 0.033*
Treatment (RT vs RT+TMZ) 12/68 1.44 (0.70-2.98) 0.32
PROX1 protein
(<50%; 50-90%; >90%) 23/42/15 1.13 (0.76-1.68) 0.53
HR= Hazard ratio; CI = confidence interval; m = missing data
#n = 77 patients in the multivariate analysis; *p ≤ 0.05
Figure 2: Photomicrographs of immunostaining with anti-PROX1 antibodies in glioblastomas, illustrating the scoring 
of the proportion of immunoreactive cells set as: ≤ 50% (left), 50-90% (middle) or ≥ 90% (right) of the total amount 
of tumor cells.
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database (http://gliovis.bioinfo.cnio.es/). We selected IDH-
wildtype glioblastomas and excluded tumors with 1p19q 
codeletion. Quantitative data for PROX1 expression and 
survival data were collected for a total number of 103 
patients (mean age 62.9 years, range 24-89 years; mean 
survival 11.4 months, range 0.2-47.6 months; dead/alive 
77/26) (Supplementary Data, Table 1). Of these, 42 were 
MGMT promoter methylated, 61 had unmethylated MGMT 
promoter. Cases for which MGMT promoter methylation 
status was unknown were not included. Cox regression, 
using age and PROX1 gene expression as continuous 
variables and MGMT promoter methylation status as 
dichotomized variable, identified age as an independent 
prognostic factor (p = 0.02) (Table 4a). No statistically 
significant pairwise interactions were found between 
PROX1 and MGMT methylation status in the model.
IDH-mutant, 1p19q non-codeleted, astrocytomas 
grade III-IV (n = 110)
In the final step, we selected IDH-mutant 
astrocytomas grade III and IDH-mutant glioblastomas, 
excluding tumors with 1p19q codeletion. Thus, a total 
number of 110 IDH-mutant tumors (103 astrocytomas 
grade III and 7 glioblastomas) were included (mean 
age 38.1 years, range 21-76; mean survival 32.1, range 
0-139 months; dead/alive 24/86) (Supplementary Data, 
Table 2). Of these cases, 99 had MGMT promoter 
methylation, 11 had unmethylated MGMT promoter. 
Cases with undetermined MGMT promoter methylation 
status were not included. Multivariate survival analysis 
by Cox regression, with age and PROX1 entered as 
continuous variables and MGMT promoter methylation as 
dichotomized variable, identified PROX1 gene expression 
as an independent prognostic factor (p = 0.0001), together 
with MGMT promoter methylation (p = 0.04) and WHO 
grade (p = 0.02), while age did not reach significance (p 
= 0.08) (Table 4b). 
DISCUSSION
In the present study we have unraveled the role of 
PROX1 as a prognostic factor for patients with high-grade 
astrocytomas. In three consecutive steps, we showed that 
PROX1 protein levels correlated with survival for patients 
with IDH-mutant high-grade astrocytomas but not for 
patients with primary glioblastomas. These findings were 
confirmed by PROX1 gene expression analysis in tumors 
extracted from TCGA that were 1p19q non-codeleted 
and stratified by IDH mutation status. Together with our 
previous studies in low-grade gliomas, we conclude that 
PROX1 is a pathway-specific biomarker for IDH-mutant, 
1p19q non-codeleted astrocytomas that may be used to 
identify high-risk patients. So far, there are few clinically 
useful biomarkers to predict individual outcome and guide 
clinical management for these patients [17]. Our results 
are of clinical importance and warrant the implementation 
of PROX1 in future trials of adults with IDH-mutant 
astrocytomas to further establish its role as a prognostic 
biomarker and potential treatment target.
The different cohorts that were used in this study 
are a strength but also a limitation of the present study. 
Our screening set consisted of a single-institution cohort 
of high-grade astrocytomas irrespective of IDH mutation 
status for which clinical data collection was performed 
post-hoc. The age-specific cohorts, on the other hand, 
were treatment cohorts of patients with glioblastomas 
enrolled in prospective clinical trials. DNA sequencing 
to verify that these were IDH-wildtype glioblastomas 
was performed for patients aged younger than 60 years, 
but not for patients aged 60 years and older enrolled in 
these trials. It is most likely that this cohort of elderly 
patients with newly diagnosed glioblastomas that 
lacked immunoreactivity for mIDH1R132 consisted of 
primary glioblastomas. However, the most recent WHO 
classification of brain tumors has reserved the diagnosis 
“glioblastomas NOS” for tumors for which full IDH1/2 
evaluation cannot be performed [5]. 
Due to the low number of IDH-mutant glioblastomas 
in our TMAs and in TCGA, we were not able to compare 
survival by PROX1 expression for patients with secondary 
glioblastomas separately. To obtain a representative group 
of IDH-mutant high-grade astrocytomas for PROX1 
protein analysis, we collected the IDH1 immunopositive 
(mIDH1R132) and IDH-mutated 1p19q non-codeleted 
tumors in our TMAs. For studying PROX1 gene 
expression in correlation to survival, we extracted IDH-
mutant 1p19q non-codeleted anaplastic astrocytomas and 
glioblastomas from TCGA. The low number of IDH-
mutant glioblastomas is consistent with the low incidence 
of secondary glioblastomas, comprising only around 10% 
of all glioblastoma cases [18]. In this context, it should be 
noted that the mean survival in the group of patients with 
IDH-mutant high-grade astrocytomas was significantly 
longer than in primary glioblastomas (32.1 months versus 
11.4 months, tumors derived from TCGA). The negative 
results for PROX1 in the group of primary glioblastomas 
Table 3: Multivariate Cox regression in IDH-mutant anaplastic astrocytomas and glioblastomas (n = 34)
Variables n HR (95% CI) p-value
Age  1.03 (1.00-1.07) 0.047*
Malignancy grade (WHO III vs IV) 20/14 0.81 (0.53-1.25) 0.34
PROX1 protein (< 50% vs ≥ 50%) 24/10 0.37 (0.16-0-94) 0.037*
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may therefore also exemplify the general difficulties to 
identify new biomarkers for patients with such a short 
survival time [19, 20]. 
Like other homeodomain containing proteins, 
PROX1 is able to both activate and repress transcription 
of genes in a context-dependent manner. The relationship 
between PROX1 and cancer is complex, and PROX1 can 
either exhibit tumor suppressing or oncogenic properties, 
depending on cancer type [7]. Interestingly, data 
extracted from TCGA displayed a statistically significant 
correlation between PROX1 gene expression and survival 
for patients with IDH-mutant, 1p19q non-codeleted low-
grade astrocytomas, but not with IDH-wildtype or 1p19q 
codeleted low-grade gliomas (Supplementary Figure 1). 
Thus, it seems that the prognostic impact of PROX1 in 
low-grade gliomas is also pathway-dependent, consistent 
with our findings in high-grade astrocytomas. Whether 
PROX1 is a lineage-specific prognostic marker (i.e. for 
astrocytomas but not for oligodendrogliomas) is still 
unknown and needs to be studied further. 
The diverting roles of PROX1 in IDH-mutant and 
IDH-wildtype astrocytomas may be related to different 
epigenetic regulatory mechanisms between these tumor 
types. IDH-wildtype glioblastomas predominate in 
elderly patients who have a generally higher degree of 
genomic methylation [21]. Promoter hypermethylation 
may be a regulatory mechanism for PROX1 that is tumor 
type-specific, depending on cellular context and specific 
signaling pathways [22]. Indeed, PROX1 was one of 
the identified target genes that were hypermethylated 
in a DNA screening of urine from patients with bladder 
cancer [23]. Aberrant DNA methylation of PROX1 causing 
gene silencing has also been reported in hematological 
cancer [22]. A recent multi-platform genomic analysis of 
gliomas identified a subtype of IDH-mutant low-grade 
glioma that was associated with DNA demethylation and 
Figure 3: Kaplan Meier estimates of survival for 34 patients with IDH-mutant astocytomas grade III and IV included 
in the TMAs, with low (< 50%) versus high level (≥ 50%) of PROX1 protein.
Table 4a: Multivariate Cox regression in IDH-wildtype glioblastomas extracted from the Cancer Genome Atlas (n=103)
Variables HR (95% CI) p-value
Age 103 1.03 (1.00-1.05) 0.020*
MGMT status
(methyl vs unmethyl) 42/61 0.67 (0.41-1.10) 0.11
PROX1 mRNA 103 0.90 (0.74-1.08) 0.25
HR= hazard ratio; CI = confidence interval; *p ≤ 0.05
Table 4b: Multivariate Cox regression in IDH-mutant anaplastic astrocytomas and glioblastomas extracted from the 
Cancer Genome Atlas (n=110)
 Variables HR (95% CI) p-value
Age 110 1.04 (1.00-1.07) 0.082
Grade (III vs. IV) 103/7 0.14 (0.04-0.68) 0.018*
MGMT status(methyl vs unmethyl) 99/11 0.19 (0.05-0.78) 0.040*
PROX1 mRNA 110 5.07 (1.07-13.06) 0.0001*
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poor outcome [24]. It was also shown that tumors with 
high extent of genome-wide methylation could emerge 
as low methylated at recurrence, suggesting that DNA 
methylation is one of the mechanisms driving glioma 
progression [24]. 
High age is strongly associated with glioma 
incidence [25]. Age at disease onset is also one of the 
strongest single predictors for survival in all glioma 
types [13, 26]. It is largely unknown how aging affects 
glioma malignancy, but there is increasing evidence for 
fundamental molecular differences between high-grade 
gliomas of different age groups. Tumors of elderly patients 
with glioblastomas usually lack markers associated with 
favorable prognosis in the younger population [27]. It 
has been suggested that normal aging predisposes neural 
progenitor cells (NPCs) to increased malignant potential 
[28]. NPCs are tissue-specific progenitor cells that are the 
presumed cells of origin for gliomas [29,30], although 
differentiated cells such as astrocytes may also give rise to 
gliomas by dedifferentiation [31]. Age-related changes in 
the microenvironment of NPCs contribute to the increased 
cancer risk in the older brain [28]. The present study does 
not provide evidence for PROX1 as an age-dependent 
prognostic marker in primary glioblastomas. Instead, we 
found that PROX1 is a predictor for survival in the group 
of high-grade 1p19q non-codeleted astrocytomas that are 
IDH-mutant and predominate in younger patients with a 
prior history of low-grade gliomas. 
In conclusion, the transcription factor PROX1, with 
a widespread role in CNS development, is a prognostic 
marker for IDH-mutant high-grade astrocytomas that 
evolve through multi-step genetic alterations over 
time. Together with our previous study in low-grade 
gliomas [12], we propose that PROX1 is a clinically 
valuable biomarker to predict the course of disease for 
these patients. Future studies are needed to clarify the 
mechanisms by which PROX1 leads to tumor progression 
and affects clinical outcome in this patient group. 
MATERIALS AND METHODS
Patient cohorts
Screening cohort of unselected high-grade 
astrocytomas
For PROX1 protein screening we selected 86 
astrocytomas WHO grade III and IV from a TMA of a 
previously described retrospective cohort of 96 adult 
patients with high-grade gliomas [15]. Oligodendroglial 
tumors were excluded based on histological tumor 
diagnosis. Mutated IDH1 (R132H) protein was detected 
by immunohistochemistry. Molecular characterization for 
detection of IDH1/2 mutations, 1p19q codeletions and 
MGMT promoter methylation status was not performed. 
All patients received RT, concomitant and adjuvant TMZ 
was not used consistent with standard protocols at that 
time. Thirty-one patients received chemotherapy and 19 
patients had proton radiation as second-line treatment [15]. 
Survival was defined as the time point between surgery 
and date of death. All patients had died at the end of 
the study. Data concerning time of death and the cause 
of death were collected from central health authorities. 
Tissues were obtained and used in a manner compliant 
with the Declaration of Helsinki. The local ethical 
committee approved the study protocol (Application Dnr 
Ups 02-330).
Cohort of elderly patients with newly diagnosed 
glioblastoma
In the context of the Nordic trial for patients 
aged 60 years or older with glioblastoma, a TMA was 
constructed as a powerful tool to screen candidate 
markers for response to therapy or outcome in this 
trial [14]. The TMA comprised 175 paraffin embedded 
glioblastoma tissues from patients enrolled in the trial 
divided over three treatment-arms; standard RT 60 
Gy (n = 49), hypofractionated RT 34 Gy (n = 58) and 
temozolomide (n = 67). Study treatment was started in 
65 of the 67 patients in the temozolomide group, 46/49 
patients in the standard RT group, and 57/58 patients in 
the hypofractionated RT group. Second-line treatment, 
where reported, in the temozolomide group was: 9 
chemotherapy, 27 RT, 4 re-operation, 1 bevacizumab and 
1 imatinib, in the hypofractionated RT: 20 chemotherapy, 
1 re-radiation and 1 re-operation, and in the 60 Gy RT 
group: 18 chemotherapy, 1 re-radiation, 2 re-operation 
and 2 bevacisumab. The TMA was constructed with an 
agarose matrix at the Service of Neurosurgery, Lausanne 
University Hospital, Switzerland [31]. Mutated IDH1 
(R132H) protein was detected by immunohistochemistry 
on TMA or whole tumor sections. Molecular 
characterization of MGMT promoter methylation status 
was performed, but not of IDH1/2 mutations and 1p19q 
codeletions.
Cohort of younger patients with primary glioblastoma
To represent the younger population of 
glioblastomas, we used a TMA from patients aged 18-
60 years with high-grade gliomas enrolled in a treatment 
cohort with RT or RT and TMZ in various combinations. 
Inclusion criteria were histologically proven astrocytoma 
grade III or IV and age 18-60 years. A total of 145 
patients were included between 2003-2008 and 110 tumor 
samples were available for construction of TMA and DNA 
extraction. Molecular characterization included analysis of 
1p19q codeletion, MGMT promoter methylation status and 
IDH1/2 mutations. The present study describes the results 
for 80 patients with IDH-wildtype glioblastomas, and for 
19 additional patients with IDH-mutant astrocytoma grade 
III or IV that were included in this TMA. Data collection 
included molecular tumor markers, histological diagnosis, 
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age, treatment arm (RT versus RT plus TMZ), type of 
surgery, WHO performance status, steroids at baseline, 
and overall survival. 
Immunohistochemistry
Immunohistochemical staining and slide scanning 
was performed in accordance with strategies used in 
The Human Protein Atlas project (www.proteinatlas.org) 
[33]. Immunostainings were performed at the SciLifeLab 
Tissue Profiling Facility, Uppsala University, Sweden 
[34]. Automated immunohistochemistry was performed as 
previously described using a LabVision Autostainer 480S 
(Thermo Fisher Scientific, Runcorn, UK) [35]. 
Antibodies
Immunostaining for supportive verification of the 
histopathological diagnosis included diagnostic antibodies 
directed to glial fibrillary acidic protein (GFAP) (1:500; 
polyclonal rabbit, DAKO, Denmark), microtubule-
associated protein 2 (MAP2) (1:100; mouse clone HM2, 
Sigma), Ki67 (1:500; rabbit polyclonal, DAKO), and 
mutated isocitrate dehydrogenase 1 (IDH1) R132H protein 
(1:100; monoclonal mouse antibody, mIDH1R132) [16]. 
For detection of PROX1 we used rabbit anti-PROX1 
(HPA000385; 1:100 dilution) [12]. 
Evaluation of immunohistochemistry
At least two observers (TE, JC, KRR, AS) 
independently evaluated the immunostainings and 
assessed the proportion of labeled tumor cells in each 
sample. The entire section of microtissue was examined. 
In case of diversities (approximately 15% of all evaluated 
samples in this study), the scoring results were re-
evaluated by the two observers to reach consensus. The 
fraction of labeled tumor cells was graded manually into 
a 3-grade scale: 1 (+) = < 50% strong positive tumor 
cells; 2 (++) = ≥ 50% and < 90% strong positive tumor 
cells; 3 (+++) = ≥ 90% strong positive tumor cells. Clear 
and distinct immunoreaction was considered as positive 
staining, while faint and less distinct immunoreaction was 
considered negative. 
Molecular analyses
MGMT promoter methylation
A modified pyrosequencing method published 
by Collins et al. was used to assess MGMT methylation 
status [36]. After bisulfite modification of 50-200 
ng of DNA using EZ DNA Methylation Kit (Zymo 
Research), nested PCR was carried out with HotStarTaq 
Master Mix (Qiagen), annealing temperature of 
51°C and primers: forward primer, primary PCR 
TTTAYGTYGTTATTTTTGTGTTTTT, forward primer, 
secondary PCR GTTTYGGATATGTTGGGATAG, 
reverse primer used in both reactions biotin-
AAAACCACTCRAAACTACCAC. Obtained PCR 
product was used as a template in 4 pyrosequencing 
assays. In brief, per one assay 15 µl of the PCR product 
was mixed with 40 µl of binding buffer, 23 µl of water 
and 2 µl of sepharose beads (GE Healthcare). Biotinylated 
DNA strand bound to the beads was isolated with a 
Vacuum Prep Workstation (Qiagen) and moved to the 
15 µl of mixture containing 0.3 µM sequencing primer 
in the annealing buffer. Sequencing primer was annealed 
to the template at 80°C for 2 min. Pyrosequencing 
was performed on a PyroMark Q96 MD instrument 
(Qiagen) using PyroMark Gold Q96 CDT Reagents 
(Qiagen). Sequencing primers, sequences to analyze and 
dispensation orders for each pyrosequencing assay were 
as follows: amplicon1- GATAGTTYGYGTTTTTAGAA, 
YGTTTTGYGTTTYGAYGTTYGTAGGTTTT, 
ATCGTTCAGTCTGTTCGTATCAGTCGTCA; 
amplicon2-TTTYGAYGTTYGTAGGTTT, 
YGYGGTGYGTATYGTTTGYGA, 
GTCTGTCGTAGTCGTGATCGTAGTCGA; 
amplicon3-GYGATTTGGTGAGTGTTTG, 
GGTYGTTTYGTTTTYGGAAGAGTGYGG, 
AGTCTGTTCAGTTCGAGAGTAGTCG; amplicon4- 
GAAGAGTGYGGAGTTTTTTTT, YGGGAYGG, 
ATCGTATCG. Samples were run in duplicates and 
triplicates. Pyrosequencing data were analyzed using Pyro 
Q-CpG software version 1.0.9, giving % methylation for 
each CpG site. Mean values for each site from different 
runs were used to calculate the mean methylation value 
for the entire region. Samples with a mean value of 
methylation from all 16 CpGs < 9 % were considered 
unmethylated and ≥ 9% as methylated, this cut-off 
providing the most significant survival difference among 
patients with IDH-wildtype tumor.
Mutation analysis of IDH
IDH mutation status was confirmed by 
pyrosequencing. In the pyrosequencing assay a 108bp 
long PCR product was amplified using following 
primers: biotin-CAAAAATATCCCCCGGCTTG 
and ACATGCAAAATCACATTATTGCC in the 
concentration of 1 µM each mixed with 1 U MyTaq 
DNA polymerase (Bioline), 5 mM MyTaq Buffer and 
20 ng of template DNA in a final volume of 20 µl. The 
annealing temperature was 57°C. The confirmation of 
successful amplification was done by 1,5% agarose 
gel electrophoresis. Single-stranded template was 
prepared as described above and annealed to the 
sequencing primer ACTTACTTGATCCCCATAAGCAT. 
For the following sequence to analyze GA[T/C]
GACCTATGATAGGTTTTACCCA, dispensation order of 
CGATCTCGAC was used. Reagents and instrument were 
used as previously mentioned. Data were analyzed using 
PyroMark MD 1.0 software.
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Evaluation of 1p19q codeletion
Codeletion on chromosome 1p19q was investigated 
using droplet digital PCR. The method was based on the 
detection of changes in the copy numbers of genes located 
on arms 1p and 19q (1p13.2 LRIG2, 1p31.1 FUBP1, 
1p32.3 CDKN2C and 19q12 CCNE1, 19q13.11 CEBPA, 
19q13.32 ERCC1) using the QX100 Droplet Digital PCR 
system (BioRad). In case of loss of one copy in all of 
the genes, 1p19q codeletion was stated. Samples were 
subjected to six reactions, each dedicated to a specific 
gene. Ten ng of the DNA isolated from paraffin sections 
was mixed with 11 µl of ddPCR Supermix for Probes 
(BioRad), 1.1 µl of the probe for the gene of interest 
and 1.1 µl of the probe for the reference gene in the final 
volume of 22 µl. Manufacturer’s recommendations for 
the preparation of droplets and the PCR were applied 
on all of the genes except FUBP1, where the annealing 
temperature was raised to 61°C. The following probes 
have been used: CDKN2C (dHsaCP1000589, BioRad), 
CEBPA (dHsaCP1000494, BioRad) with reference AP3B1 
(dHsaCP2500348) and FUBP1 (Hs05722030, Applied 
Biosystems), LRIG2 (Hs06588310, Applied Biosystems), 
CCNE1 (Hs01813172, Applied Biosystems) and ERCC1 
(Hs01171620, Applied Biosystems) with reference 
AP3B1 (dHsaCP1000001, BioRad), what was dictated 
by the differences in the length of the probes. Probes 
for the genes were labelled with FAM dye and for the 
reference gene with HEX dye. Data was analyzed using 
the QuantaSoft software v. 1.2.10 (BioRad) and automated 
clustering analysis [37].
The Cancer Genome Atlas
To confirm the results obtained by the TMAs on 
the correlation between PROX1 expression and patient 
survival we extracted data from TCGA (http://gliovis.
bioinfo.cnio.es/) (last update 8th May 2016). We included 
all astrocytomas WHO grade III and glioblastomas for 
which comprehensive data on PROX1 transcriptome, 
IDH mutation status, MGMT promoter methylation status, 
survival time and patient age were available. Tumors 
harboring codeletions on chromosomes 1p and 19q were 
excluded. Two separate datasets, one comprising 110 IDH-
wildtype glioblastomas (TCGA Dataset IDH-wildtype, 
Supplementary Table 1) and one comprising 103 IDH-
mutant astrocytomas grade III/IV (TCGA Dataset IDH-
mutant, Supplementary Table 2) were analyzed. For 
survival analysis PROX1mRNA and patient age were used 
as continuous variables, and MGMT promoter methylation 
status as dichotomized variable.
Statistical analysis
Survival curves were plotted according to the 
Kaplan-Meier method (product-limit method) and the 
log-rank probability test estimated the prognostic value 
of PROX1 and other variables by univariate analysis. 
Multivariate Cox regression was used to calculate hazards 
ratios (HR) for relative risk of death. We tested for 
pairwise interactions between PROX1 and the variables 
MGMT promoter methylation, IDH mutation and patient 
age. Statistical analysis was performed in JMP, version 
10.0 (SAS Institute Inc., Cary, North Carolina, USA) and 
in SPSS, version 22. 
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